ViroLogic improves PhenoSense sensitivity
This article was originally published in Clinica
Executive Summary
ViroLogic has developed an improved version of its PhenoSense HIV assay with a fivefold greater sensitivity, the company announced at the International AIDS Society meeting in Buenos Aires, Argentina earlier this month. While the original PhenoSense assay, which is used to measure HIV resistance to antiviral drugs, can give a result when there are as few as 500 viral particles per millilitre of blood, the new version works with viral levels as low as 100 per millilitre.